ERSP on CigArrest
This article was originally published in The Tan Sheet
Executive Summary
CigArrest, marketer of the eponymous smoking cessation program, has adequately supported its general performance and safety claims, but should modify or discontinue its claim that users can "become a non-smoker in as little as seven days," according to an Electronic Retailing Self-Regulation Program decision Feb. 24. ERSP reviewed a TV ad and website promoting the product and expressed concern about claims such as: "clinically proven methods to help you avoid smoking in any situation" and "the most successful stop smoking program." However, the National Advertising Review Council division found that ingredient claims such as "the active ingredients work...by relieving nervous tension, irritability and the craving associated with withdrawal" were given "adequate" support by scientific literature. Additionally, safety claims including "all-natural, non-addictive" and "we have not had any serious reactions or adverse side-effects ever reported" were reasonably supported by the marketer, ERSP states. CigArrest is a homeopathic formula that includes Nux Vomica (poison nut) and Plantago Major (plantain), the marketer states...
You may also be interested in...
ERSP Review Of Claims Lights Fire Under Smoking-Cessation Marketer
Final Smoke Inc. voluntarily modifies claims for its smoking-cessation system, including a dietary supplement and homeopathic detoxification liquid, in conjunction with an Electronic Retailing Self-Regulation Program review
Roche/Genentech Keeps Commitment To External Cancer Innovation
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: